Venaxis, Inc., formerly AspenBio Pharma, Inc., is focused on products that address unmet human diagnostic needs. The Company is developing a multi-marker blood test panel, APPY1, which is focused to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2-20) that present with abdominal pain. As on December 31, 2013, the Company�s research and development activities are focused primarily on a human acute appendicitis blood-based test. APPY1 is a multi-marker blood test panel of biomarkers consisting of the Company�s patented MRP 8/14 (also known as S100A8/A9 or calprotectin) and C-reactive protein (CRP), along with White Blood Cell count (WBC). These results are displayed on the display screen and are also included on a patient printout from the APPY reader, which is a small bioanalyzer (instrument or reader).